05/21/2026
This is amazing news and a huge announcement for osteosarcoma and Ewing sarcoma patients!!!!
This Is BIG: The BCC023 Trial using DFMO for Ewing Sarcoma and Osteosarcoma is NOW ENROLLING!!!!
What This Is: DFMO (Eflornithine) for Ewing Sarcoma and Osteosarcoma
What This Means: Ewing sarcoma and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation. There have been no real advancements to the standard of care in decades. By incorporating DFMO (eflornithine) as an additional therapy and/or maintenance therapy, our team of experts believe to observe improved event-free survival and overall survival.
Why This Matters: With little to no change to treatment protocol since the standards of care were developed, this trial provides an additional, less-toxic form of therapy for children battling these pediatric sarcomas. DFMO has been shown to successfully prevent relapse in neuroblastoma and laboratory research indicates the same results may be seen in sarcomas. This trial represents hope for countless children and families.
Anyone wishing to enroll immediately will have to travel to Penn State Health in Hershey until other sites begin to open. For enrollment information, please email: [email protected]
Research: Beat Childhood Cancer